Comprehensive Stock Comparison
Compare Amarin Corporation plc (AMRN) vs Zai Lab Limited (ZLAB) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | ZLAB | 15.3% revenue growth vs AMRN's -25.5% |
| Quality / Margins | AMRN | -38.0% net margin vs ZLAB's -38.1% |
| Stability / Safety | AMRN | Beta 0.84 vs ZLAB's 0.99, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | AMRN | +27.3% vs ZLAB's -44.5% |
| Efficiency (ROA) | AMRN | -13.1% ROA vs ZLAB's -15.0%, ROIC -18.7% vs -42.8% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Amarin Corporation is a pharmaceutical company focused on developing and commercializing cardiovascular therapeutics. It generates nearly all its revenue from VASCEPA — a prescription omega-3 fatty acid product for reducing triglyceride levels — sold primarily to wholesalers and specialty pharmacies. Its key advantage is patent protection and regulatory exclusivity for VASCEPA, though this moat faces challenges from generic competition.
Zai Lab is a biopharmaceutical company that licenses, develops, and commercializes innovative therapies for oncology, autoimmune disorders, and infectious diseases primarily in Greater China. It generates revenue through product sales of its commercialized drugs — like Zejula for ovarian cancer and NUZYRA for bacterial infections — supplemented by milestone payments and royalties from its extensive partnership network. The company's key advantage lies in its strategic licensing model that gives it exclusive rights to promising late-stage and commercial-stage therapies for the Greater China market, allowing it to build a diversified portfolio without bearing full R&D costs.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
AMRN leads in 4 of 6 categories (Financial Metrics, Valuation Metrics). ZLAB leads in 1 (Total Returns).
Financial Metrics (TTM)
ZLAB is the larger business by revenue, generating $460M annually — 2.0x AMRN's $227M. Profitability is closely matched — net margins range from -38.0% (AMRN) to -38.1% (ZLAB).
| Metric | AMRNAmarin Corporatio… | ZLABZai Lab Limited |
|---|---|---|
| RevenueTrailing 12 months | $227M | $460M |
| EBITDAEarnings before interest/tax | -$93M | -$218M |
| Net IncomeAfter-tax profit | -$86M | -$176M |
| Free Cash FlowCash after capex | -$22M | -$159M |
| Gross MarginGross profit ÷ Revenue | +38.9% | +58.6% |
| Operating MarginEBIT ÷ Revenue | -42.5% | -49.9% |
| Net MarginNet income ÷ Revenue | -38.0% | -38.1% |
| FCF MarginFCF ÷ Revenue | -9.6% | -34.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +17.4% | +17.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +69.7% | +43.8% |
Valuation Metrics
| Metric | AMRNAmarin Corporatio… | ZLABZai Lab Limited |
|---|---|---|
| Market CapShares × price | $5.7B | $21.3B |
| Enterprise ValueMkt cap + debt − cash | $5.6B | $20.8B |
| Trailing P/EPrice ÷ TTM EPS | -3.45x | -12.01x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 25.11x | 46.21x |
| Price / BookPrice ÷ Book value/share | 0.58x | 2.94x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
AMRN delivers a -18.8% return on equity — every $100 of shareholder capital generates $-19 in annual profit, vs $-25 for ZLAB. AMRN carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to ZLAB's 0.31x. On the Piotroski fundamental quality scale (0–9), ZLAB scores 3/9 vs AMRN's 2/9, reflecting mixed financial health.
| Metric | AMRNAmarin Corporatio… | ZLABZai Lab Limited |
|---|---|---|
| ROE (TTM)Return on equity | -18.8% | -24.5% |
| ROA (TTM)Return on assets | -13.1% | -15.0% |
| ROICReturn on invested capital | -18.7% | -42.8% |
| ROCEReturn on capital employed | -17.0% | -27.9% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 3 |
| Debt / EquityFinancial leverage | 0.02x | 0.31x |
| Net DebtTotal debt minus cash | -$113M | -$455M |
| Cash & Equiv.Liquid assets | $121M | $680M |
| Total DebtShort + long-term debt | $8M | $224M |
| Interest CoverageEBIT ÷ Interest expense | -7085.14x | -48.75x |
Total Returns (with DRIP)
A $10,000 investment in ZLAB five years ago would be worth $1,186 today (with dividends reinvested), compared to $1,115 for AMRN. Over the past 12 months, AMRN leads with a +27.3% total return vs ZLAB's -44.5%. The 3-year compound annual growth rate (CAGR) favors ZLAB at -19.7% vs AMRN's -30.2% — a key indicator of consistent wealth creation.
| Metric | AMRNAmarin Corporatio… | ZLABZai Lab Limited |
|---|---|---|
| YTD ReturnYear-to-date | +0.6% | +10.9% |
| 1-Year ReturnPast 12 months | +27.3% | -44.5% |
| 3-Year ReturnCumulative with dividends | -66.0% | -48.3% |
| 5-Year ReturnCumulative with dividends | -88.9% | -88.1% |
| 10-Year ReturnCumulative with dividends | -52.7% | -31.2% |
| CAGR (3Y)Annualised 3-year return | -30.2% | -19.7% |
Risk & Volatility
AMRN is the less volatile stock with a 0.84 beta — it tends to amplify market swings less than ZLAB's 0.99 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMRN currently trades 66.0% from its 52-week high vs ZLAB's 43.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AMRNAmarin Corporatio… | ZLABZai Lab Limited |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.84x | 0.99x |
| 52-Week HighHighest price in past year | $20.90 | $44.34 |
| 52-Week LowLowest price in past year | $7.08 | $15.96 |
| % of 52W HighCurrent price vs 52-week peak | +66.0% | +43.3% |
| RSI (14)Momentum oscillator 0–100 | 40.0 | 57.7 |
| Avg Volume (50D)Average daily shares traded | 76K | 622K |
Analyst Outlook
Wall Street rates AMRN as "Hold" and ZLAB as "Buy". Consensus price targets imply 82.1% upside for ZLAB (target: $35) vs -84.3% for AMRN (target: $2).
| Metric | AMRNAmarin Corporatio… | ZLABZai Lab Limited |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $2.17 | $35.00 |
| # AnalystsCovering analysts | 18 | 11 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Feb 20 | Feb 26 | Change |
|---|---|---|---|
| Amarin Corporation … (AMRN) | 100 | 5.11 | -94.9% |
| Zai Lab Limited (ZLAB) | 100 | 29.65 | -70.3% |
Zai Lab Limited (ZLAB) returned -88% over 5 years vs Amarin Corporation … (AMRN)'s -89%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Amarin Corporation … (AMRN) | $130M | $229M | +75.7% |
| Zai Lab Limited (ZLAB) | $0.00 | $460M | — |
Zai Lab Limited's revenue grew from $0M (2016) to $460M (2025) — a 0.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Amarin Corporation … (AMRN) | -66.4% | -35.9% | +45.8% |
| Zai Lab Limited (ZLAB) | -1074.3% | -38.1% | +96.4% |
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Amarin Corporation … (AMRN) | -8.2 | -4 | +51.2% |
| Zai Lab Limited (ZLAB) | -39.7 | -1.6 | +96.0% |
Zai Lab Limited's EPS grew from $-39.70 (2016) to $-1.60 (2025).
Chart 5Free Cash Flow — 5 Years
Amarin Corporation plc generated $-31M FCF in 2024 (+53% vs 2021). Zai Lab Limited generated $-159M FCF in 2025 (+72% vs 2021).
AMRN vs ZLAB: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is AMRN or ZLAB a better buy right now?
Analysts rate Zai Lab Limited (ZLAB) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AMRN or ZLAB?
Over the past 5 years, Zai Lab Limited (ZLAB) delivered a total return of -88.1%, compared to -88.9% for Amarin Corporation plc (AMRN). A $10,000 investment in ZLAB five years ago would be worth approximately $1K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ZLAB returned -31.2% versus AMRN's -52.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AMRN or ZLAB?
By beta (market sensitivity over 5 years), Amarin Corporation plc (AMRN) is the lower-risk stock at 0.84β versus Zai Lab Limited's 0.99β — meaning ZLAB is approximately 18% more volatile than AMRN relative to the S&P 500. On balance sheet safety, Amarin Corporation plc (AMRN) carries a lower debt/equity ratio of 2% versus 31% for Zai Lab Limited — giving it more financial flexibility in a downturn.
04Which has better profit margins — AMRN or ZLAB?
Amarin Corporation plc (AMRN) is the more profitable company, earning -35.9% net margin versus -38.1% for Zai Lab Limited — meaning it keeps -35.9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMRN leads at -40.2% versus -49.9% for ZLAB. At the gross margin level — before operating expenses — ZLAB leads at 58.6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — AMRN or ZLAB?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is AMRN or ZLAB better for a retirement portfolio?
For long-horizon retirement investors, Amarin Corporation plc (AMRN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.84)). Both have compounded well over 10 years (AMRN: -52.7%, ZLAB: -31.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between AMRN and ZLAB?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.